Entry offers an astonishing risk reward ratio up to 20.55
### NOT FINANCIAL ADVICE###
Комментарий
⋅
It seems the price has been rejected by the double top. Also the MRNA is dropping, will be watching how it goes, not going to take the trade if correlations are in the way.
Looks like a double-top. ALSO looks like an 'M' - I'm going contrarian here and saying it has a lot of trouble getting its vaccine FDA-approved, possibly ever, resulting in a price descent that mirrors its price ascent to its 1997 high.